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Abstract
Pulmonary Embolism Response Team (PERT) is a multidisciplinary team established to stratify risk 
and choose optimal treatment in patients with acute pulmonary embolism (PE). Established for the 
first time at Massachusetts General Hospital in 2013, PERT is based on a concept combining a Rapid  
Response Team and a Heart Team. The growing role of PERTs in making individual therapeutic decisions  
is identified, especially in hemodynamically unstable patients with contraindications to thrombolysis or 
with co-morbidities, as well as in patients with intermediate-high risk in whom a therapeutic decision 
may be difficult. The purpose of this document is to define the standards of PERT under Polish condi-
tions, based on the experience of teams already operating in Poland, which formed an agreement called 
the Polish PERT Initiative. The goals of Polish PERT Initiative are: improving the treatment of patients 
with PE at local, regional and national levels, gathering, assessing and sharing data on the effectiveness 
of PE treatment (including various types of catheter-directed therapy), education on optimal treatment 
of PE, creating expert documents and supporting scientific research, as well as cooperation with other 
communities and scientific societies. (Cardiol J 2019; 26, 6: 623–632)
Key words: pulmonary embolism, pulmonary embolism response team,  
catheter-directed therapy, embolectomy
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Introduction. PERT definition.  
Polish PERT Initiative
Acute pulmonary embolism (PE) is one of the 
most common diseases of the cardiovascular sys-
tem. It is estimated that PE occurs at a frequency 
of 39–115/100,000 population/year and causes 
over 400,000 deaths in Europe every year [1–3]. 
It is the third most frequent vascular disease, 
after myocardial infarction and stroke [1, 2]. The 
clinical presentation of PE is heterogenous: from 
mild impairment of exercise tolerance (low-risk 
PE), through severe dyspnoe with symptoms of 
right ventricular overload (intermediate-risk PE) 
to hemodynamic collapse, “obstructive” shock and 
death (high-risk patients) most often related to 
acute insufficiency of the right ventricle (RV) and 
respiratory failure [1–3]. Although most patients 
with PE can be successfully treated with anticoagu-
lants, hemodynamically unstable patients require 
urgent systemic thrombolysis (ST). Thrombolytic 
therapy, however, has significant limitations. First 
of all, it is associated with a significant increase in 
the risk of major bleeding (13%), including up to 
3% of patients treated with ST, who have dangerous 
intracranial bleeding, mainly cerebral hemorrhagic 
stroke [4]. In the group of patients of the ZATPOL 
— Polish national prospective registry, it has been 
shown that the occurrence of major bleeding in 
acute PE significantly worsened the prognosis [5]. 
In high-risk (hemodynamically unstable) patients, 
the clinical benefit of thrombolysis exceeds the 
risk of bleeding, but in intermediate-risk patients 
the potential clinical benefit of ST does not balance 
the risk of major bleeding and does not reduce 
mortality [6]. On the other hand, about 5–10% of 
patients who are initially hemodynamically stable 
may experience a sudden and unexpected clinical 
deterioration [7]. According to the guidelines of 
the European Society of Cardiology, in the case 
of contraindications to thrombolysis or its failure, 
surgical embolectomy is recommended [3]. How-
ever, a severe preoperative condition and high 
incidence of comorbidities, as well as limited avail-
ability of cardiac surgery result in high mortality 
in this group. Furthermore, it has been shown that 
thrombolytic therapy is often not used in high-risk 
patients, even though there are no contraindica-
tions [8]. Moreover, in intermediate-high-risk 
patients, the decision on thrombolysis or surgical 
therapy is often taken too late, and hemodynamic 
deterioration in this group of patients is associ-
ated with high mortality [9]. Consequently, new 
techniques for transcatheter invasive treatment of 
PE (catheter-directed therapy [CDT]) have been 
developed, which can remove thrombi from the pul-
monary arteries without the additional risks posed 
by systemic thrombolysis or cardiac surgery. In 
the last decade, many new devices and techniques 
have been proposed for transcatheter treatment 
of PE [10]. There is also a growing number of 
scientific data from clinical observational studies 
and registries confirming the clinical effectiveness 
of interventional treatment with a reduction in 
the number of patients with significant bleeding. 
However, only few randomized trials comparing 
CDT with standard anticoagulant and thrombolytic 
therapy are available in the literature [11, 12]. 
Nonetheless, quick and correct diagnosis, proper 
risk stratification and selection of optimal therapy 
from a constantly growing pharmacological and 
intervention armamentarium, seems to be crucial 
in patients with acute PE.
In 2013, in Massachusetts General Hospital 
in Boston (United States), the world’s first multi-
specialist team was created for quick consultation 
and selection of the therapy in patients with PE 
[13]. This team was named the Pulmonary Embo-
lism Response Team (PERT). The PERT concept 
was based on a combination of two other proven 
clinical practice models: The Heart Team and the 
Rapid Response Team [14, 15]. The growing role 
of PERTs in making individual therapeutic deci-
sions is pointed out, especially in hemodynami-
cally unstable patients with contraindications to 
thrombolysis (e.g. with active bleeding shortly 
after surgery) or with significant co-morbidities 
(including cancers), as well as in patients with 
intermediate-high risk patients in whom this treat-
ment may accelerate clinical improvement and 
improve prognosis [13–15]. Treatment methods 
should also include various methods of CDT as 
an alternative to ST and surgical embolectomy. 
The current guidelines of the European Society 
of Cardiology recommended set-up (class recom-
mendations IIa/level of evidence C) of in-hospital 
PERTs adapted to local resources and access to 
specialists [3].
The purpose of this document is to define the 
standards of PERT under Polish conditions, based 
on the experience of teams already operating in 
Poland, which was formed in April 2019 an agree-
ment called the Polish PERT Initiative (PPI). The 
goals of PPI are improving the treatment of patients 
with PE at local, regional and national levels, in-
volving gathering, assessing and sharing of data 
on the effectiveness of PE treatment (including 
various types of CDT), disseminating the knowl-
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edge about optimal treatment of PE, optimizing 
financing of procedures in this area, creating expert 
documents and supporting scientific research, as 
well as cooperating with other communities and 
scientific societies.
PERT models, interdisciplinary  
cooperation, minimal organizational  
and institutional framework
A clear organization model of PERT has yet 
to be defined. The world’s first PERT from Massa-
chusetts General Hospital involved specialists from 
various fields, serving for immediate consultation 
and selection of therapy in patients with PE [16]. 
The first PERT served as a model for other medi-
cal centers and soon these centers combined their 
experience within the National PERT Consortium 
[17]. The data presented by the PERT Consortium 
shows a vast diversity in the organization of teams 
and the patient population they are dealing with 
[18, 19]. The essence of PERT’s activity is to 
coordinate the diagnostic and therapeutic process 
of patients with PE of severe or atypical course by 
choosing the optimal management strategy based 
on the expert knowledge of a multidisciplinary 
team of specialists of whom it is comprised.
The PERT coordinator should be continuously 
available by phone (24/7) on a dedicated phone 
number and after accepting the application must 
be able to organize  quick consultations (< 30 min) 
with relevant specialists. These consultations may 
be a teleconference, during which all participants 
have access to a patient’s medical data and imag-
ing tests. The PERT should include specialists 
with practical experience in the treatment of acute 
PE using various methods, as well as experts to 
assist in case of complications or the presence of 
comorbidities that require modification of standard 
methods of acute PE. Among the physicians di-
rectly involved in the process of treating a patient 
upon PERT care there are usually specialists who 
have experience in the field of intensive cardiac 
therapy, echocardiography and interventional car-
diology, as well as cardiac surgeons, specialists 
in emergency medicine, anesthesiologists and 
radiologists, including interventional radiologists. 
The second group of specialists whose consulta-
tions may be necessary in selected cases should 
include neurologists, neurosurgeons, oncologists, 
vascular surgeons, hematologists and specialists 
in lung disease. It seems that the specialists listed 
in the first group should constitute a permanent 
PERT team. However, the final composition of 
PERT varies between centers and depends on re-
sources and experience. The most important tasks 
of PERT in the acute phase of PE include choosing 
optimal pharmacotherapy (including determining 
indications or contraindications for thrombolysis), 
interventional treatment (thrombus fragmentation, 
CDT, venous filter implantation) or cardiac surgery 
(pulmonary embolectomy). For those reasons, the 
ideal organizational solution is to create PERT in 
hospitals with all available treatment options in one 
location. If PERT is located in a hospital without 
a cardiac surgery department, it should have the 
formal cooperation with a cardiac surgery center 
ensuring the possibility of immediate transfer of 
patients for further treatment. Optimally, every 
PERT should have access to treatment with extra 
corporeal membrane oxygenation (ECMO) device, 
which is the equipment of cardiac surgery depart-
ments in Poland. In addition to the acute phase of 
PE treatment, the role of PERT may be to support 
the optimization of management in subsequent 
months, including determining the method and 
duration of chronic anticoagulation, possible im-
plantation of the inferior vena cava filter and patient 
monitoring for the occurrence of chronic thrombo-
embolic pulmonary hypertension (CTEPH).
Risk stratification in PE,  
qualification to treatment
Hemodynamically unstable patients, i.e. with 
systemic hypotension, in shock, requiring infusion 
of catecholamines or cardiopulmonary resuscita-
tion constitute a group of patients with high risk of 
early death with early mortality exceeding 15% and 
contain about 5% of patients with PE. Hypotonia 
is defined as systolic blood pressure < 90 mmHg 
or a decrease in systolic blood pressure of at least 
40 mmHg for > 15 min if it is not associated with 
new arrhythmias, hypovolemia or sepsis. Confir-
mation of the diagnosis of high-risk PE is not only 
the finding of RV dysfunction in echocardiographic 
or tomographic assessment [3]. 
Patients with high-risk PE require immediate 
reperfusion treatment. Systemic thrombolysis in 
high-risk PE patients is recommended as class I 
(evidence level B), surgical embolectomy as class I 
recommendation (evidence level C), and catheter-
directed therapy as class IIa recommendation 
(evidence level C) [3]. Among initially hemody-
namically stable patients with the presence of RV 
overload and positive markers of myocardial over-
load, 5–10% will develop hemodynamic instability 
despite anticoagulation [6]. Therefore, patients 
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Table 1. Bova score — risk stratification scale in medium-risk acute pulmonary embolism.
Parameter Points
Systolic pressure 90–100 mmHg 2
Elevated troponin concentration (above the cutoff level) 2
Right ventricle dysfunction: 2
Echocardiography: ≥ 1 of the following: RV/LV > 0.9, sPAP > 30 mmHg, RV diameter  
> 30 mm, or RV hypokinesis; 
Multidetector computed tomography: RV/LV > 1
Tachycardia > 110/min 1
≥ 5 points – 30-day risk:
    42% complications (death of PE, decompensation, recurrence of acute PE);
    10% mortality in PE
LV — left ventricle; PE — pulmonary embolism; RV —  right ventricle; sPAP — systolic pulmonary artery pressure.
with intermediate-high-risk PE at an early stage 
of hospitalization require monitoring, preferably in 
an intensive care unit. In the case of hemodynamic 
instability, it is advisable to implement thrombo-
lytic treatment (class I recommendation/evidence 
level B), for which the alternative is surgical 
embolectomy or CDT (class IIa recommendation/ 
/evidence level C) [3]. The Bova scale allows the 
identification of patients at risk of decompensation 
and death dependent on PE from among initially 
stable hemodynamically stable patients (Table 1) [20].
Interventional therapy in PE
At the beginning of transcatheter therapy for 
a patient with PE, a pulmonary artery angiography 
from the femoral or internal jugular vein should be 
performed initially using 5–7 F diameter pigtail 
catheters [21]. Pulmonary angiography enables 
visualization of thrombi not only in the main pul-
monary, lobar or segmental arteries but even in 
smaller (subsegmental) vessels. During pulmonary 
angiography, hemodynamic measurements should 
be made in the right atrium and right ventricle, 
and the pulmonary trunk to assess the severity 
of PE and exclude the overlapping of acute PE on 
CTEPH. Mechanical reperfusion involves the in-
troduction of a catheter into the pulmonary arteries 
from the femoral or internal jugular vein to remove 
thrombi and reduce pulmonary resistance, facilitate 
the return of RV function, improve the patient’s 
clinical condition and prognosis [22]. Percutaneous 
embolectomy involves a variety of methods, from 
mechanical thrombus fragmentation, to thrombus 
aspiration and a pharmacomechanical approach 
of mechanical or ultrasound-assisted thrombus 
fragmentation with local administration of reduced-
dose thrombolysis (Table 2). Before the procedure, 
one should perform echocardiographic examination 
not only to assess RV function, but also to exclude 
thrombi in the right heart cavities and exclude 
thrombosis in the punctured femoral vein. In the 
published meta-analysis of Bajaj et al. [23], peri-
procedural success, defined as hemodynamic sta-
bilization, reduction of hypoxia and discharge from 
hospital, was achieved in 87% of patients treated 
with endovascular treatment. The first Polish ex-
periences with transcatheter methods (AngioJet 
system, Indigo Penumbra aspiration thrombectomy, 
EKOS system and Cleaner system) have recently 
been published [24–29]. 
Another interventional technique supporting 
the treatment of acute PE is the implantation of 
vascular filters into the inferior vena cava. Venous 
filters protect the patient’s pulmonary arteries 
from subsequent embolism from deep veins of the 
lower extremities or the pelvic venous plexus. The 
results of PREPIC studies indicate that venous 
filters reduce the incidence of PE, while slightly 
increasing the incidence of venous thrombosis, 
without reducing overall mortality [30, 31]. In 
a recent analysis of the database of an American 
health fund, which included 16,950 patients with 
PE and concomitant cancer, a venous filter was 
used in 19% of patients. A reduction of mortal-
ity was demonstrated in a group of patients > 60 
years of age in whom the filter was implanted, in 
relation to the group of conservatively treated 
patients [32]. Current European Society of Car-
diology guidelines recommend the implantation 
of venous filters in patients with PE and absolute 
contraindications to anticoagulation or in patients 
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Table 2. Selected methods of catheter-directed therapy in patients with acute pulmonary embolism.
Transcatheter therapies with local thrombolysis Transcatheter therapies without thrombolysis
Method Catheter/device Method Catheter/device
Rheolytic thrombectomy 
with local thrombolysis 
AngioJet PE® catheter 6 F 
with the local thrombolysis 
application system
Rheolytic  
thrombectomy
6 F AngioJet PE® catheter 
(Boston Scientific,  
Minneapolis, MN, USA)
Power Pulse™ (Boston  
Scientific, Minneapolis, 
MN USA)
Ultrasound assisted  
catheter-directed  
thrombolysis 
EkoSonic® 5.2 F  
(EKOS, Boston Scientfic,  
Minneapolis, MN, USA)
Aspiration  
therombectomy
Aspirex® 8 F, 10 F catheters 
(Straub Medical, Switzerland): 
Angiovac cannula  
— veno-venous bypass  
(26 F – 16–20 F access)  
(AngioDynamics, Latham,  
NY, USA): 
Continuous aspiration catheter 
Indigo® (Penumbra,  
Alameda, CA, USA):  
8 F catheter connected  
to the suction pump
Aspiration using vacuum 
(40–60 mL syringe) with  
guiding catheter (e.g. 8–9 F 
multi-purpose catheter)
Mechanical  
thrombectomy 
Flowtriever® (Inari Medical, 
Irvine, CA, USA):  
20 F catheter and the  
device made by three  
self-expanding nitinol  
disks
Thrombus fragmentation 
with local thrombolysis
Pigtail catheters (5–6 F)  
or balloon catheters  
(5–10 mm)
Thrombus  
fragmentation
Pigtail catheters (5–6 F)   
or balloon catheters  
(5–10 mm)
who have recurrent PE despite adequate treatment 
(class IIa recommendation/evidence level C) [3]. 
Currently, the standard is an application of retriev-
able filters, which can be used in patients with PE 
or venous thrombosis before extensive surgery 
requiring temporary cessation of anticoagulation. 
After stabilization of the patient’s condition and 
resolution of contraindications to anticoagulation, 
removal of the filter should always be considered. 
Depending on the type of filter, it can be removed 
up to 6 months after implantation [33].
Methods of surgical treatment of PE.  
Application of ECMO
In high-risk PE, surgical pulmonary embolec-
tomy should be used in patients with absolute 
contraindications to thrombolytic therapy or if it 
is ineffective and should be considered in selected 
patients at intermediate risk [3, 34, 35]. A separate 
group consists of patients with thrombi passing 
from the right atrium to the left side through the 
patent foramen ovale.
Pulmonary embolectomy can be performed 
in any center equipped with an extracorporeal 
circulation device. Under Polish conditions, mainly 
cardiac surgery centers with their personnel and 
equipment are accessible. 
An alternative and attractive tool can also be 
mobile devices that are extracorporeal techniques 
(ECLS/ECMO), in which, by using quick access 
through peripheral vessels, it is possible to stabi-
lize the patient in shock or hypotension. The prior 
mentioned devices for extracorporeal perfusion 
techniques are more and more often used in areas 
of modern intensive therapy of critical states. 
In the Wielkopolska region, the PERT program 
was created in parallel with the program of univer-
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sal access to extracorporeal techniques, includ-
ing ECMO, as part of an organizational program 
“ECMO for Wielkopolska” (ECMO for Greater 
Poland) [36–38]. Such organizational cooperation 
gives a real chance to use a wide spectrum of 
applications in extracorporeal techniques in PE 
therapy, particularly for high risk associated with 
cardiogenic shock [38].
Extracorporeal techniques with the use of 
ECMO in PE therapy with potential use in the 
treatment of PE are as follows:
1. Veno-arterial (VA) ECMO — as a partial RV 
bypass in cardiogenic shock with hypotension:
• As part of extended cardiopulmonary 
resuscitation when PE is the cause of 
in-hospital cardiac arrest or out-hospital 
cardiac arrest;
• As a bridge to surgical embolectomy or 
transcatheter therapy;
• As RV support after surgical embolectomy 
in extracorporeal circulation;
• As a support during parenteral heparin 
anticoagulation.
2. Veno-arteriovenous (VA-V) ECMO — inciden-
tally in the treatment of shock with concomi-
tant RV failure as a RV assist device.
3. Veno-venous (VV) ECMO — incidentally after 
pulmonary embolism therapy with concomi-
tant refractory respiratory failure with hypoxia 
and hypercapnia.
4. Partial VV Angiovac system with the possibil-
ity of conversion to VA ECMO.
PERT: Proposed operating model
As PERT is modeled on a philosophy of rapid 
response, it is crucial to constitute a clear and 
sound operating protocol [13–16]. This protocol 
should accommodate PERT structure, activation 
pathways and operating mode. There are two basic 
elements of any PERT operating model. First of 
all, the PERT activation should be accessible via 
a commonly known telephone number. A dedicated 
on-call PERT consultant should be ready to answer 
a PERT activation call. The activation call may come 
from any healthcare provider in the region (district 
Referring
hospital
24
TREATMENT
Clinical assessment
Initial treatment
Advice:
• No reperfusion needed - A/C at site
• Reperfusion needed:
 • ST at site
 • referral 
a
c
ti
v
a
ti
o
n
PERT consultant
PERT specialist(s)
Invasive cardiologist
Anesthesiologist
ECMO Team
Cardiac surgeon
Other(s)
PERT center ER
Figure 1. Proposed Pulmonary Embolism Response Team (PERT) operating model. A dedicated PERT consultant is 
ready 24/7 to respond to  an activation call from a regional healthcare provider, collect necessery information on the 
patient consulted and contact an on-call PERT specialist(s) to determine whether reperfusion therapy is needed, and 
discuss treatment options. Their conclusion is communicated back to the referring physician as PERT therapeutic 
advice, which may include: (1) continue anticoagulation at the referring site, in cases where no reperfusion is re-
quired; (2) start systemic thrombolysis at the site immediately if shock or cardiac arrest is present; (3) transfer the 
patient to a PERT center, if reperfusion is required and there are contraindications to systemic thrombolysis, risk of 
major bleeding is high or the patient needs surgical intervention. ECMO — extracorporeal membrane oxygenation; 
A/C — anticoagulation; ST — systemic thrombolysis; ER — emergency room.
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hospital, outpatient clinic, ambulance) networked 
with the PERT center in a hub-and-spoke model. 
The role of the PERT consultant is to collect nec-
essary information on the patient consulted from 
a referring physician, including: clinical status and 
duration of symptoms, PE burden and hemody-
namic significance, RV function and adverse out-
come risk factors, comorbidities, contraindications 
to specific treatments like thrombolysis, surgical 
embolectomy or CDT. To facilitate the process of 
data collection, a standardized form should be in 
use (see the next paragraph). Depending on the 
PERT center institutional policies, structure and 
personnel resources, the PERT consultant may be 
an intentionally dedicated individual or any other 
on-call physician, who is capable of executing the 
PERT operating model upon activation.   
The second key element of the PERT operat-
ing model is cooperation between PERT special-
ists. The on-call PERT specialists including, at 
least, an interventional cardiologist and cardiac 
surgeon who should be ready to enter coopera-
tion upon a PERT consultant request. There are 
several modes of PERT specialist mobilization, 
among which a staged approach seems to be the 
most resource efficient and practical (Fig. 1). In 
contrast to activation of all PERT members up-
front, in the staged model the PERT consultant 
initially contacts one on-call PERT specialist to 
determine whether reperfusion therapy is needed 
and discuss treatment options. If a decision  is not 
possible, another PERT specialist(s) may be asked 
for an opinion. After reaching a final conclusion it 
is communicated back to the referring physician 
as a PERT therapeutic recommendation. The goal 
should be to complete this process within 30 min 
from activation. 
If no reperfusion therapy is required at the 
time of consultation, the patient may continue 
anticoagulation treatment at the referring hospital. 
The referring physician should stay in touch with 
the PERT center in case a patient deteriorates. 
If, in contrast, reperfusion therapy is indicated at 
the site, systemic thrombolysis should primarily 
Figure 2. Proposed therapeutic algorithm in acute pulmonary embolism for the use of Pulmonary Embolism Re-
sponse Teams. A/C — anticoagulation; CDT — catheter-directed therapy; CTPA — computed tomography pulmonary 
angio graphy; ECMO — extracorporeal membrane oxygenation; Embol — surgical embolectomy; HR — heart rate; 
PE — pulmonary embolism; RV/LV — right-to-left ventricular dimeter index; SatO2 — arterial blood oxygen saturation; 
SBP — systolic blood pressure; ST — systemic thrombolysis; sPESI — simplified Pulmonary Embolism Severity 
Index; TTE — transthoracic echocardiography; *If ST is contraindicated or has failed; #Monitoring and observing 
period of the deterioration/improvement of the patient’s condition should be individualized depending on clinical 
conditions and should not exceed 6–12 hours to decide on intensification of treatment.
Acute PE
Shock/Hemodynamic instability?
No
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Both positive One positive
RV/LV > 1
(TTE or CTPA)
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High risk
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2
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Hospitalization
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Hospitalization
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be considered, or if contraindications to ST are 
present, risk of major bleeding is high or surgi-
cal intervention is needed, the patient should be 
transferred to the PERT center. To support the 
decision-making process a therapeutic algorithm 
may be adapted (Fig. 2).
Communication and data collection tools
To promote rapid and efficient course of 
PERT consultations, it may be useful to formulate 
PERT activation and decision cards. These docu-
ments should i.e. contain referral center contact 
details, patient demographic data, duration of 
symptoms, distribution of thrombi in computed to-
mography, clinical status and risk of death defined 
by contemporary algorithms (e.g. Bova score), 
comorbidities, risk factors of venous thrombo-
embolism, contraindications to thrombolysis and 
anticipated risk of bleeding complications. Said 
forms may then serve as a background for the 
PERT decision-making process. With the advent 
of modern technologies, it has become available 
to acquire PERT activation documents in the 
form of mobile applications (Fig. 3). Use of mobile 
technologies is expected to make the process of 
data collection easier and more universal and 
to facilitate sharing information between PERT 
specialists during consultations.
It is also desirable to record data on activa-
tions, operating modes, PERT decisions and pa-
tient follow-up in the form of a registry. A regular 
evaluation of accumulated data should provide 
insight in general PE quality measures such as 
mortality and morbidity, but also PERT — specific 
measures such as: time from activation to decision, 
time from decision to therapeutic anticoagulation 
or to reperfusion therapy, methods and effects of 
reperfusion treatment, PERT structure and activa-
tion modes, application of contemporary guidelines, 
etc. Such data may also help to improve knowledge 
on the role of PERT in acute PE care.
Figure 3. Mobile application developed by the Pulmonary Embolism Response Team (PERT) of the John Paul II Hos-
pital in Krakow, Poland and is used to collect pulmonary embolism patient data and to conduct PERT consultations.
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Conclusions
1. Organization of multidisciplinary PERT in 
reference centers for management of high- and 
intermediate-high risk PE is recommended 
depending on local resources and available 
expertise.
2. The most important tasks of PERT in the acute 
phase of PE include choosing optimal pharma-
cotherapy (including determining indications 
or contraindications for thrombolysis), inter-
ventional treatment (catheter-directed therapy, 
venous filter implantation) or cardiac surgery 
(pulmonary embolectomy).
3. It is crucial to constitute a clear and sound 
operating protocol. Such protocol should ac-
commodate the PERT structure, activation 
pathways and operating mode.
4. A PERT coordinator should continuously be 
available by phone (24/7) on a dedicated phone 
number and after accepting the application 
must be able to organize a quick consultation 
(< 30 min) with relevant specialists.
5. Among the physicians directly involved in the 
process of treating a patient under PERT care 
there are usually specialists who have experi-
ence in the field of intensive cardiac therapy, 
echocardiography and interventional cardiol-
ogy, as well as cardiac surgeons, specialists in 
emergency medicine, anesthesiologists and ra-
diologists including interventional radio logists.
6. The second group of specialists whose con-
sultations may be necessary in selected cases 
should include neurologists, neurosurgeons, 
oncologists, vascular surgeons, hematologists 
and specialists in lung diseases.
7. To promote rapid and efficient course of PERT 
consultations, it may be useful to formulate 
PERT activation and decision cards (if pos-
sible, in the form of mobile applications).
PERTs operating in Poland
• Centrum Interwencyjnego Leczenia 
Zatorowości Płucnej (CELZAT); Depart-
ment and Faculty of Cardiology, Medical Uni-
versity of Warsaw; Banacha 1a, tel: 691 520 108; 
Department of Pulmonary Circulation, Throm-
boembolic Diseases and Cardiology European 
Health Center, Otwock, tel: 22 710 30 58
• POZ-PERT — Pulmonary Embolism 
Response Team at Lord’s Transfigura- 
tion University Hospital, Poznan University 
of Medical Sciences, Poznań, tel: 608 574 375
• DJ-PERT — Pulmonary Embolism Re-
sponse Team at the Infant Jesus Universi-
ty Hospital; Lindleya 4, Warsaw, Department 
of Internal Medicine and Cardiology, Medical 
University of Warsaw, Poland, tel: 507 121 347/ 
/507 121 367
• Pulmonary Embolism Response Team 
at the John Paul II Hospital in Krakow 
(PERTJPII), tel: 606 762 306
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